Cat.No. : CSC-RO0618 Host Cell: MC38
| Cat. No. | CSC-RO0618 |
| Description | This cell line is derived from MC38 and is engineered to stably overexpress Human CD19. |
| Gene | CD19 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | MC38 |
| Host Cell Species | Mus musculus (Mouse) |
| Stability | Validated for at least 10 passages |
| Application | 1. Studying the interactions between immune cells and cancer cells 2. Studying the mechanisms of resistance to immune checkpoint blockade 3. High-throughput screening 4. Drug target validation |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
The clinical application of CAR-T cell therapy is accompanied by potential adverse effects, notably cytokine storms, which result from the substantial release of cytokines as CAR-T cells proliferate within the body. Researchers developed exosomes expressing CD19 Chimeric Antigen Receptor (Exo-CD19 CAR), demonstrating cytotoxicity specifically against CD19-positive leukemia B-cells while sparing CD19-negative cells. This innovation presents a safer alternative to CAR-T cell therapy, mitigating the risk of cytokine storms. Exo-CD19 CAR exosomes offer a promising nano-immunotherapy strategy for B-cell leukemia treatment, capitalizing on their targeted cytotoxicity and reduced adverse effects compared to conventional CAR-T cell therapy.
Figure 1. Researchers utilized CD19 Stable Cell Line in HEK293T cells for CD19 CAR exosome production. Transfected cells showed ~39% eGFP expression, confirming successful transfection. After two rounds of cell sorting, ~92% eGFP-positive cells were achieved. This demonstrates stable transfection and active CD19 CAR plasmid expression in HEK293T cells for exosome production. (Haque S, et al., 2021)
A: HEK293T cells were likely selected for their high transfection efficiency and suitability for stable transgene expression, facilitating the study of EPCAM biology and its role in cancer and epithelial cell function.
A: Stability was likely assessed through methods such as flow cytometry, immunoblotting, or functional assays measuring EPCAM-mediated signaling, with continuous selection pressure applied.
A: Characterization may involve analysis of EPCAM membrane localization, interaction with binding partners, downstream signaling pathways, and functional implications in cell adhesion, migration, or cancer progression.
A: Quality control likely included confirmation of EPCAM expression levels, validation of its functional activity, assessment of off-target effects, and validation of phenotypic changes associated with EPCAM modulation.
A: Comparative analysis with primary epithelial cells or in vivo models helps validate the relevance of EPCAM expression in tumor initiation, progression, and metastasis, guiding the development of EPCAM-targeted therapeutics for cancer treatment.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Exceptional consistency! The Human CD19 Stable Cell Line in MC38 cells ensures reliable CD19 expression, facilitating precise and reproducible results in my immunology research.
Empowering advanced studies! With stable CD19 expression, I can explore B cell biology and immunotherapy mechanisms with confidence, driving innovation in the field.
Impressive performance! This cell line goes above and beyond, providing a robust platform for investigating CD19-targeted therapies and cancer immunotherapy approaches.
Streamlining research processes! Its stable expression simplifies experimental workflows, enhancing efficiency and enabling in-depth data analysis.
An invaluable asset! The Human CD19 Stable Cell Line has revolutionized my research, offering valuable insights into CD19-mediated immune responses and therapeutic strategies for cancer treatment.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
